Revenue and Sales Performance - Revenue for the three months ended June 30, 2023, was $23.5 million, an increase of $6.2 million, or 36.2%, compared to the same period in 2022[117]. - Surgical Glaucoma revenue for the six months ended June 30, 2023, was $38.7 million, with gross margins of 87.6%[105]. - Dry Eye segment revenue for the six months ended June 30, 2023, was $3.6 million, with a gross margin of 54.4%, up from $2.3 million and 0.6% in the prior year[105]. - Surgical Glaucoma sales represented 91.2% of total revenue for the three months ended June 30, 2023[117]. - Revenue for the six months ended June 30, 2023, was $42.3 million, an increase of $10.2 million or 31.7% from the prior year, driven by increased sales of OMNI and SION units in the Surgical Glaucoma segment[125]. Financial Position and Cash Flow - As of June 30, 2023, the company had cash and cash equivalents of $154.5 million and an accumulated deficit of $271.1 million[107]. - The company expects that its current cash and cash equivalents, along with revenue from product sales, will fund operations for at least the next 12 months[140]. - The company had a net cash used in operating activities of $30.9 million for the six months ended June 30, 2023, an improvement from $40.3 million in the prior year[134]. Expenses and Margins - The cost of goods sold for the three months ended June 30, 2023, was $3.4 million, an increase of $0.6 million from $2.7 million in the prior year[118]. - Research and development expenses for the three months ended June 30, 2023, were $5.2 million, a decrease of 11.9% from the prior year[117]. - Total gross profit for the three months ended June 30, 2023, was $20.1 million, an increase of $5.6 million from the same period in 2022, with a gross margin of 85.6%[119]. - Gross margin for the six months ended June 30, 2023, increased to 84.8%, up from 82.0% in the prior year, primarily due to the impact of a voluntary recall in the Dry Eye segment[127]. - Selling, General, and Administrative expenses were $58.7 million for the six months ended June 30, 2023, a decrease of $1.1 million from the prior year, mainly due to lower marketing and consulting expenses[130]. Debt and Financing - The company expects to continue incurring net losses for at least the next several years and may seek additional debt and equity financing[106]. - The Term Loan agreement has a maturity date of November 1, 2025, with a floating interest rate of SOFR plus 7.00%, and principal payments are expected to begin in December 2023, potentially delayed to December 2024[145]. - A final payment fee of 6.0% on the $35.0 million Term Loan balance has been partially accrued, totaling $1.4 million as of June 30, 2023[145]. - Interest expense increased by $0.5 million for the six months ended June 30, 2023, attributed to rising lending rates compared to the same period in 2022[131]. Internal Controls and Accounting - A material weakness in internal control over financial reporting was identified, related to insufficient accounting personnel with requisite experience[156]. - Remediation efforts have been implemented, but not all aspects of the material weakness have been sufficiently addressed[158]. - No changes in internal control over financial reporting have materially affected the company's controls during the most recent fiscal quarter[159]. - There have been no material changes to critical accounting policies and estimates compared to the previous year[150]. - The company has elected to use an extended transition period under the JOBS Act, which may affect the comparability of its financial statements with other public companies[152]. - As of June 30, 2023, there are no significant Accounting Standard Updates expected to materially impact the financial statements[153]. Research and Development - Research and Development expenses decreased by $1.7 million during the six months ended June 30, 2023, primarily due to reductions in clinical studies and personnel costs[129]. - The company has dedicated significant resources to expand its sales organization and improve market access for TearCare[102]. Other Income - Other income, net was $3.6 million for the six months ended June 30, 2023, compared to $0.1 million in the prior year, due to amortization of purchase discounts on investments[132]. Leases - The company leases approximately 11,000 square feet of office and R&D space in Menlo Park, California, and 2,040 square feet in Southlake, Texas, with lease expirations in 2024[147].

Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Philip Tailor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Craig Bijou - Bank of America Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2023 Earnings Conference Call. At this time, all parti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (St ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Phillip Dantoin - Piper Sandler Thomas Stephan - Stifel Michael Arens - William Blair Operator Good day and thank you for standing by. Welcome to the Sight Sciences First Quarter 2023 Earnings Results Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) 4040 Campbell Ave, Suite 100 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission Fi ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive Officer Jim Rodberg - Interim Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Thomas Stephan - Stifel Financial Corp. Craig Bijou - Bank of America Securities, Inc. Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Margaret Kaczor - William Blair Matthew O'Brien - P ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley David Saxon - Needham & company Thomas Stephan - Stifel Financial Corp. Craig Bijou - Bank of America Securities, Inc. Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Thi ...

Business Overview - The company's mission is to transform ophthalmology and optometry by targeting the underlying causes of prevalent eye diseases[5] - The company focuses on surgical glaucoma and dry eye, with products aimed at restoring natural functionality of diseased eyes[5,6] Market Opportunity - The U S Total Addressable Market (TAM) for surgical glaucoma is $6 billion with over 120,000 cases performed[7] - The U S TAM for dry eye is $10 billion with over 20,000 cases performed, and 86% of DED cases are associated with MGD[8] - The standalone MIGS segment represents a $5 billion U S market opportunity[8] Financial Performance - Q2 Revenue was $17 2 million, a 37% year-over-year increase[93] - Surgical Glaucoma revenue was $15 9 million, a 33% year-over-year increase[93] - Dry Eye revenue was $1 3 million, a 143% year-over-year increase[93] Products and Clinical Trials - OMNI is indicated for use in both combination cataract and standalone MIGS procedures for primary open-angle glaucoma (POAG)[15] - TearCare is indicated for patients with evaporative DED due to MGD[8] - The OLYMPIA RCT showed that a single use of TearCare successfully reduced signs and symptoms of DED within 2 weeks[60]

Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Andrew Brackmann - William Blair Matthew O'Brien - Piper Sandler Joanne Wuensch - Citibank Tom Stephan - Stifel Operator Hello and welcome to the Sight Sciences' Second Quarter 2022 Earnings Results Conferenc ...

™ Delivering the Power of Sight Investor Presentation May 2022 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements ...